Test - Ascendis Pharma JP

NEWS RELEASES

August 4, 2022

Ascendis Pharma A/S Announces Second Quarter 2022 Financial Results and Business Update Conference Call on August 10

June 7, 2022

Ascendis Pharma A/S Announces Two Oral Presentations Highlighting the Potential for TransCon™ PTH to be a Replacement Therapy for Adult Hypoparathyroidism at ENDO 2022

May 23, 2022

Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharma’s Phase 3 Height Trial

Preclinical

Phase 1

Phase 2

Phase 3

TransCon hGH

Pediatric growth hormone deficiency2

test

Phase 1

test

Adult growth hormone deficiency

Phase 1

TransCon PTH

Adult hypoparathyroidism

Phase 2

Preclinical

Phase 1

Phase 2

Phase 3

sss

Phase 1

sdsd

sss

Phase 2

sss

sds

Phase 3

You are about to access www.ascendispharma.us, which includes information intended for U.S. residents only. Click below to confirm.

CONFIRM DENY

You are about to access www.ascendispharma.com. Click below if you wish to proceed.

CONFIRM DENY

You are about to leave the Ascendis Pharma website and will continue on an external website. Ascendis Pharma takes no responsibility for the content of such external website

CONFIRM DENY